What are the treatment recommendations for B-cell mantle cell lymphoma (MCL)?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN and ESMO offer similar treatment recommendations, as follows [16, 31]

  • Chemotherapy followed by involved-site radiation therapy (ISRT), 30-36 Gy, is the preferred treatment option for limited stage I or II (non-bulky) disease, although this presentation is rare

  • For advanced-stage disease in younger patients and selected elderly fit patients, the recommended approach is aggressive induction therapy, followed by consolidation therapy consisting of high-dose therapy with autologous stem cell rescue

  • Prophylaxis and monitoring for tumor lysis syndrome should be strongly considered during the induction therapy.

  • In elderly fit patients, less-aggressive induction regimens followed by rituximab maintenance is recommended by both NCCN and ESMO

  • For elderly patients who are not candidates for any of the above chemotherapy regimens, palliative chemotherapy should be considered, using milder chemo-immunotherapy regimens (eg, chlorambucil plus rituximab, bendamustine plus rituximab)

  • For relapsed or refractory disease, recommendations include high-dose therapy with autologous stem cell rescue and second-line agents; allogeneic stem cell transplantation can be considered in selected patients as part of a second-line consolidation

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!